Table 4. Univariate logistic regression analysis of potential risk factor in predicting CMV reactivation in CMV seropositive kidney transplant recipients that did not receive thymoglobulin.

DM: diabetes mellitus; I/S: immunosuppression; BKV: BK polyomavirus; ppx: prophylaxis; GCV: ganciclovir; VGCV: valganciclovir.

Univariate Logistic Regression (n=77)
Variable	n (%)	Any CMV PCR		CMV PCR 450+ IU/ml¥
		p	Odds ratio (95% CI)	p	Odds ratio (95% CI)
Older age cohort	45 (58.44)	0.0008	1.44 (1.17,1.76)	0.174	1.17 (0.93, 1.47)
Sex female	26 (33.77)	0.954	1.01 (0.80, 1.27)	0.688	1.05 (0.83, 1.33)
DM	32 (42.86)	0.0413	1.25 (1.01, 1.55)	0.163	1.18 (0.94,1.48)
Prior transplant	8 (10.39)	0.012	0.64 (0.46,0.90)	0.0407	0.68 (0.48, 0.98)
CMV seropositive donor	49 (66.64)	0.117	1.20 (0.96, 1.49)	0.327	1.12 (0.89, 1.42)
No induction (=steroids only)	18 (23.38)	0.133	0.822 (0.64, 1.06)	0.452	0.90 (0.69, 1.18)
Basiliximab induction	59 (76.62)	0.133	1.22 (0.95, 1.56)	0.452	1.11 (0.85, 1.45)
Rejection $$	9 (11.69)	0.537	0.90 (0.64, 1.26)	0.884	0.97 (0.69, 1.38)
Augmented I/S	9 (11.69)	0.356	0.85 (0.60, 1.20)	0.585	0.90 (0.62, 1.30)
BKV	20 (25.97)	0.279	1.15 (0.90, 1.46)	0.172	1.20 (0.93, 1.54)
Use of CMV directed ppx for at least 30 days (GCV/VGCV)	13 (15.58)	0.782	0.96 (0.72, 1.28)	0.963	0.99 (0.73, 1.34)
Bacteremia	15 (19.48)	0.66	0.94 (0.72, 1.23)	0.565	0.92 (0.69, 1.22)
Pneumonia	12 (15.58)	0.893	1.02 (0.76, 1.37)	0.388	1.15 (0.84, 1.56)
Admission for infection [patient level]	36 (46.75)	0.769	1.03 (0.83, 1.28)	0.327	1.12 (0.89, 1.40)
Surgery [patient level]	20 (25.97)	0.597	0.94 (0.73, 1.20)	0.739	1.04 (0.81, 1.35)

^¥n=52

^$$Nine patients with rejection, 2 of them had 2 episodes.